Harbin Pharmaceutical Group Co., Ltd. (600664.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 7.18

From 52W high−13.38%

Volume506.91M

Market capCNY 20.70B

P/E (TTM)57.3x

P/S (TTM)1.2x

Div yield—

Key dataSep 18, 2026

Open

CNY 7.18

From 52W high

−13.38%

Volume

506.91M

Market cap

CNY 20.70B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.4x

P/E (TTM)

57.3x

RSI (14)

48.0

MomentumView details →

1D Return

+0.61%

YTD Return

+117.39%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

57.3x

EV/EBITDA

21.4x

EV/Sales

1.1x

P/S (TTM)

1.2x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

25.32%

Net Margin

1.94%

EBITDA Margin

5.14%

ROE (TTM)

5.29%

ROA (TTM)

2.11%

Asset Turnover

1.10x

GrowthView details →

Revenue YoY

−1.50%

EPS YoY

−54.73%

FCF YoY

+14.85%

Revenue CAGR 3Y

+4.95%

EPS CAGR 3Y

−9.68%

EBITDA YoY

—

MomentumView details →

1D Return

+0.61%

YTD Return

+117.39%

1Y Return

+105.48%

RSI (14)

48.0

vs 50D SMA

+4.43%

vs 200D SMA

+69.49%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

1.45x

Quick Ratio

1.17x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

CNY 0.10

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

15.96B

Net Income (TTM)

309.80M

Op. CF (TTM)

718.17M

Latest newsMore news →

Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.26d ago

Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.48d ago

Similar companies

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK Aprogen Biologics Inc.003060.KS 皓元医药688131.SH Viatris Inc.VTRS 天士力600535.SH 济川药业600566.SH Find similar companies →

Latest newsMore news →

Harbin Pharmaceutical Group announced its first-half 2026 results: net profit attributable to shareholders of 410 million yuan, up 57.99% year-on-year.26d ago Harbin Pharmaceutical announced that its subsidiaries Harbin General Factory and Harbin No.6 Factory have two products provisionally selected in the 12th national centralized drug procurement, with the procurement period lasting until December 31, 2029.48d ago